Florencia McAllister, MD
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor, Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, Genetics, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, Texas
Faculty Member, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2000 | National University of Rosario Medical School, Rosario, Santa Fe, AR, MD |
Postgraduate Training
| 2014-2014 | Research Fellowship, Tumor Immunology, Johns Hopkins University Oncology Department, Baltimore, Maryland |
| 2009-2014 | Clinical Fellowship, Medical Oncology Fellowship, Johns Hopkins University, Baltimore, Maryland |
| 2009-2012 | Clinical Fellowship, Clinical Pharmacology Fellowship Johns Hopkins University, Internal Medicine Department, Baltimore, Maryland |
| 2007-2008 | Clinical Research Certificate, Clinical Research Training Program University of Pittsburgh-School of Medicine, General Internal Medicine Department, Pittsburgh, Pennsylvania |
| 2006-2008 | Clinical Residency, Internal Medicine, UPMC Presbyterian Shadyside University of Pittsburgh Medical Center Internal Medicine Department, Pittsburgh, Pennsylvania |
| 2005-2006 | Clinical Internship, UPMC Presbyterian University of Pittsburgh Medical Center Internal Medicine Department, Pittsburgh, Pennsylvania |
| 2003-2005 | Postdoctoral Fellowship, Immunology, Children's Hospital of Pittsburgh Immunology and Host Defense Lab, Pittsburgh, Pennsylvania |
| 2002-2003 | Postdoctoral Fellowship, Gene Therapy Program, Louisiana State University, New Orleans, Louisiana |
| 2000-2001 | Clinical Internship, Carrasco Hospital Infectious Disease Center, Rosario, Santa Fe |
Licenses & Certifications
| 2023 | Medical License (GA) |
| 2023 | Medical License (MS) |
| 2023 | Medical License (AZ) |
| 2023 | Medical License (TN) |
| 2023 | Medical License (OK) |
| 2023 | Medical License (OK) |
| 2023 | Medical License (WA) |
| 2023 | Medical License (LA) |
| 2023 | Medical License (AL) |
| 2021 | Medical License (FL) |
| 2015 | Medical Oncology |
| 2015 | Medical License (TX) |
| 2010 | Internal Medicine |
| 2009 | Medical License (MD) |
Experience & Service
Faculty Academic Appointments
Associate Professor, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2024
Associate Professor, Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2024
Associate Professor, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2024
Assistant Professor, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2020
Assistant Professor, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2020
Administrative Appointments/Responsibilities
Director, Tumor Ecosystem Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Associate Director, Translational Research, Sheikh Ahmed Center for Pancreatic Cancer, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Co-Director, Immunology Program, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences Program, 2023 - 2024
Co-Leader, Pancreatic Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - Present
Lead, Preclinical Testing , PRIME-TR Microbiome Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - Present
Director, Pancreatic Cancer Genetics/High Risk Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - Present
Affiliate Member, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000 - Present
Other Professional Positions
Member, Internal Advisory Board, Neologics Bio, LLC, San Diego, CA, 2024 - Present
Member, Diversity Committee- Cancer Biology, Houston, TX, 2020 - Present
Graduate Committee Faculty, Texas A&M University, Houston, TX, 2020 - Present
Lead, Tumor Microbiome, PRIME-TR Microbiome Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2023
Instructor, National University of Rosario, Rosario, 2000 - 2002
Teaching Assistant, National University of Rosario, Rosario, 1998 - 2000
Instructor, National University of Rosario, Rosario, 1997 - 1998
Teaching Assistant, National University of Rosario, Rosario, 1995 - 1996
Extramural Institutional Committee Activities
Co-Chair, Internal Advisory Board, Institute of Data Science, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Research Space Advisory Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Wall of Science Selection Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Research Integrity Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Cancer Molecular Imaging and Theranostics (CMIT) Task Force, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Career Development Award Scientific Review, PanCAN, 2023 - Present
Volunteer, MDA 2022-1 Inquiry Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Chair, American Association of Cancer Research (AACR), The University of Texas MD Anderson Cancer Center, 2023 - 2024
Member, Research Policy Advisory Council Monthly, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Tumor Microenvironment Section of the Tumor Biology (TB) Subcommittee, American Association for Cancer Research (AACR), 2022
Member, Cancer Biology T32 Diversity Committee- Cancer Biology, The University of Texas MD Anderson Cancer Center, 2020 - 2023
Member, Tumor Immunology Steering Committee, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, 2019 - Present
Member, UT Graduate School Tumor Immunology Steering Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Tumor Immunology Steering Committee, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, 2019 - Present
Committee Member, Focus on Junior Faculty, The University of Texas MD Anderson Cancer Center, 2016 - 2018
Committee Member, Admission Committee, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, 2016 - 2018
Member, Immunology Department Faculty Recruitment Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2024
Committee Member, CCP Department Faculty Recruitment Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2023
CCP Department Representative, Infectious Disease Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2023
Editorial Activities
Scientific Editor, Cancer Discovery, 2023 - 2026
Research Proposal, The Israel Science Foundation, 2023
Editorial Board Advisor, Cell Reports Medicine, 2020 - Present
Honors & Awards
| 2023 | Roger Research Excellence Award,, Finalist |
| 2023 | Mary Beth Maddox Award for Pancreatic Tumor Microbiome Research, Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) |
| 2022 | American Society of Clinical Investigation (Honor Society) |
| 2022 | Brooks Family Endowment Fund |
| 2022 | Faculty Scholar Award, MD Anderson Cancer Center |
| 2022 | Inaugural Shelby Scholar, , Shelby-Lavine Pancreatic Cancer Research |
| 2021 | Inaugural Shelby Scholar, Shelby-Lavine Pancreatic Cancer Research |
| 2021 | MD Anderson Faculty Scholar Award, The University of Texas MD Anderson Cancer Center |
| 2020 - 2022 | Sharp Innovation Award, SU2C-AACR |
| 2019 | Duncan Family Fellow |
| 2019 | Presidential Recognition for Research Excellence, MD Anderson Cancer Center |
| 2019 | Top 10 paper in cancer in the world, European Association for Cancer Research |
| 2018 - 2019 | Andrew Sabin Fellow, Sabin Foundation |
| 2018 | Emerson Collective Scholar |
| 2016 | V Foundation Scholar, V Foundation |
| 2016 | AGA Scholar, AGA |
| 2014 | AACR/PanCAN Career Development Award, AACR/PanCAN |
| 2014 | New Faculty Award, MD Anderson |
| 2013 | GI ASCO Merit Award, GI ASCO |
| 2012 | T32 Training grant in Clinical Pharmacology, NIGMS |
| 2012 | ASCO Young Investigator Award, ASCO (CCF) |
| 2012 | AACR Basic Science Fellowship, AACR |
| 2009 | O’Toole Award, University of Pittsburgh |
| 2004 | Scholarship NIAID, Tuberculosis and Pulmonary Infections Assembly |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Pancreatic cancer: Innovation from interception to Therapy. Invited. Gastroenterology Research and Understanding with Bhutani. Houston, Texas, US.
- 2026. Cancer Epi Lecture on Pancreatic Cancer. Invited. Houston, Texas, US.
- 2026. TBA. Invited. New Orleans, LA, US.
- 2026. Tumor Microbes Shape Immunity through IFN Signaling. Invited. 6th Annual GCC Future of Immunology Symposium. Houston, Texas, US.
- 2025. Microbes shaping host immune modulation in cancer. Invited. Systems Biology Seminar Series. Houston, Texas, US.
- 2024. Microbes at the intersection of host defense and tumor fate. Invited. Cell Therapy Symposium. Houston, Texas, US.
- 2023. Microbial matters in pancreatic cancer. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2023. Mary Beth Maddox Award. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2022. Immune-Microbiome Biomarker Discovery. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2020. Technological advanced in Science. Conference. MD Anderson Cancer Center. HOUSTON, TX, US.
- 2016. Hereditary Pancreatic Cancer. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2016. Development of Pancreatic Cancer High Risk clinic. Conference. CCSG Retreat. Houston, TX, US.
- 2015. Hereditary Pancreatic Cancer. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2015. Metabolomics Symposium. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2015. Immune Cells Inducing Cancer Stemness. Conference. MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2026. TBD. Invited. The International Women’s Day Symposium at OHSU. Portland, Oregon, US.
- 2024. Role of microbes in driving cancer and therapy response. Invited. Henry Ford Symposium. Detroit, MI, US.
- 2024. TBD. Invited. Mechanisms & Models of Cancer. Cold Spring Harbor, NY, US.
- 2023. Real-time metabolic imaging for early detection of pancreatic cancer. Conference. MD Anderson Cancer Center. Virtual, US.
- 2023. Modulating the Gut and Tumor Microbiome in Pancreatic Cancer. Conference. Shelby-Lavine Pancreatic Cancer Research Symposium. Virtual, US.
- 2022. CP Member Science. Conference. MD Anderson Cancer Center. Virtual, US.
- 2014. Current Topics in Genetics. Conference. University of Texas Graduate school, TX, US.
- 2012. Speaker at the White House. Washington, DC, US.
National Presentations
- 2025. Microbes shaping Host Immune Modulation in Cancer. Invited. CNIO Distinguished Seminar Series. Madrid, ES.
- 2025. TBA. Invited. Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions. Boston, Massachusetts, US.
- 2025. Mechanisms employed by microbes and metabolites to mediate tumorigenesis. Invited. AACR Annual Meeting. Chicago, Illinois, US.
- 2025. Therapeutic implications of selective bacterial colonization of colorectal cancer. Invited. AACR Annual Meeting. Chicago, Illinois, US.
- 2024. TBD. Invited. Boston, MA, US.
- 2024. Microbial Host Defense and Influence in Cancer. Invited. San Francisco, CA, US.
- 2023. Microbial Matters in Cancer. Invited. TAMEST. San Antonio, TX, US.
- 2023. Microbial Matters in Cancer. Invited. Thursday Seminar Series. La Jolla, CA, US.
- 2023. Plenary Session 8: Therapeutic Opportunities in Tumor Stromal and Immune Microenvironments. Invited. AACR Special Conference: Pancreatic Cancer. Boston, MA, US.
- 2023. Understanding the role of the microbiome in cancer formation, progression and treatment. Invited. Cell Press. Virtual, US.
- 2023. Mechanisms employed by the gut and tumor microbiome to mediate responses to immunotherapy. Invited. AACR Annual Meeting. Orlando, FL, US.
- 2023. Plenary Session: The Phillip A. Sharp Innovation In Collaboration Awards. Invited. SU2C Scientific Summit. Coronado, CA, US.
- 2022. Microbiome within Pancreatic Tumors and Impact on Immune Microenvironment. Invited. Society for Immunotherapy of Cancer. Boston, MA, US.
- 2022. Metabolism and Microbiome. Invited. AACR Pancreatic Cancer Conference. Boston, MA, US.
- 2022. The Role of Microbes and their Induced NETs in Pancreatic Cancer. Invited. NYU Langone Health. New York, NY, US.
- 2022. Microbes in pancreatic cancer, from function to early detection. Conference. PRIME-TR. Virtual Conference, US.
- 2022. FIT TEAM: FMT. Conference. Moon Shots Scientific Seminar. Virtual Seminar, US.
- 2021. Keynote for NCCC Scientific Retreat. Conference. Dartmouth Geisel School of Medicine. Virtual Conference, US.
- 2021. Microbiome in pancreatic cancer” and “Risk groups and strategies for early detection. Conference. IATTGI, S. Oncologia Del Hospital Udaondo, US.
- 2021. Pancreatic Cancer: Microbes and their Induced Traps. Invited. Westlake University. Virtual Conference, US.
- 2021. NETosis in Pancreatic Cancer and COVID-19 AACR Annual Meeting. Invited. AACR Annual Meeting. Virtual Conference, US.
- 2021. Tumor Microbiome in Pancreatic Cancer. Invited. AACR Annual Meeting. Virtual Conference, US.
- 2021. SLAGO, Society of Latin-American GI-Oncologists. Invited. SLAGO, Society of Latin-American GI-Oncologists. Virtual Conference, US.
- 2020. APA Virtual Meeting. Conference. APA. Virtual Conference, US.
- 2020. Role of the gut-tumor microbial axis in pancreatic ductal adenocarcinoma (PDAC). Conference. AACR. Virtual Conference, US.
- 2020. The Microbiome as a Regulator of the Immune Tumor Microenvironment - Implications of finding bacteria in pancreatic tumors. Conference. AACR. Virtual Conference, US.
- 2020. Role of the Microbiome. Conference. AACR. Orlando, FL, US.
- 2020. Role of Intra-Tumoral Microbes in Pancreatic Cancer and Interaction with Gut Microbes. Conference. Society for Immunotherapy of Cancer (SITC). Orlando, FL, US.
- 2020. Genomic and therapeutic implications of selective bacterial and fungal colonization of gastrointestinal malignancies. Invited. SU2C. Santa Monica, CA, US.
- 2019. Digestive Disease Week. Invited. Digestive Disease Week. San Diego, CA, US.
- 2019. Workshop speaker, Pancreatic Cancer Tumor Microenvironment. Conference. AACR Annual Meeting. Atlanta, GA, US.
- 2018. Immune Systems and Treatment Responses. Invited. Digestive Disease Week. Washington, DC, US.
- 2018. Digestive Disease Week, Symposia Speaker. Invited. Digestive Disease Week, Symposia Speaker. Washington, DC, US.
- 2018. Poster Presentation: Pancreatic cancer immunoprevention: Novel strategies. Invited. AACR Annual Meeeting. Chicago, IL, US.
- 2018. Presenter. Invited. V Foundation Summit. Fairfax, VA, US.
- 2018. Immunology Seminar. Invited. AMGEN. Los Angeles, CA, US.
- 2018. Presentation. Invited. SU2C. Los Angeles, CA, US.
- 2017. Presentation. Invited. American Pancreatic Association. San Diego, CA, US.
- 2017. Pancreatic Disease. Invited. Gigi Shaw Arledge Conference. New York, NY, US.
- 2016. Keynote Speaker. Invited. Pancreatic Cancer Research Group/ ASCO. Chicago, IL, US.
- 2016. IL-17 induces pancreatic cancer stemness. Conference. AACR Special Meeting on Pancreatic Cancer. Orlando, TX, US.
- 2016. Updates in Pancreatic Cancer Research. Invited. PanCAN Speaker for Community Education. Houston, TX, US.
- 2015. School of Exact and Natural Sciences. Invited. University of Buenos Aires, US.
- 2015. Metabolomics Symposium. Invited. MD Anderson Cancer Center. Houston, TX, US.
- 2015. Early detection of pancreatic cancer and chemoprevention. Invited. Digestive Disease Week. Washington, DC, US.
- 2015. Amgen Guest Speaker. Invited. Immunology Seminar. Los Angeles, CA, US.
- 2014. Targeting TH17 cells in pancreatic ductal adenocarcinoma. Conference. PanCAN Retreat. Los Angeles, CA, US.
- 2014. Current Topics in Genetics. Conference. University of Texas Graduate School, TX, US.
- 2013. Pancreatic Cancer. Invited. Pancreatic Cancer Action Network, CA, US.
- 2013. Pancreatic cancer symposium. Invited. AACR. Washington, DC, US.
- 2012. Th17 cells in early pancreatic tumorigenesis. Conference. AACR Pancreatic Cancer 2012. Lake Tahoe, NV, US.
- 2012. Pancreatic cancer tumor initiating cells are marked by the presence of cell surface acetylated alpha tubulin. Conference. Pancreatic Cancer AACR Meeting. Lake Tahoe, NV, US.
- 2012. Microenvironment Symposium. Invited. AACR Annual Meeting. Chicago, IL, US.
- 2011. Clinical Pharmacology Seminar. Invited. Johns Hopkins University. Baltimore, MD, US.
- 2007. A Healthy Woman with Acute Dyspnea and Chest Pain: The Importance of family history. Conference. Society of General Internal Medicine. Toronto, Canada, US.
- 2007. Medicine Grand Rounds. Invited. University of Pittsburgh School of Medicine. Pittsburgh, PA, US.
- 2005. Cystic Fibrosis. Invited. XIX Annual North American Cystic Fibrosis Conference. Baltimore, MD, US.
- 2005. Cytokine Therapeutics. Invited. Keystone Immunology Meeting. Santa Fe, NM, US.
- 2005. Role of IL-17 and IL-23 in Cystic Fibrosis. Conference. Keystone Immunology Meeting, Cytokine Therapeutics. Santa Fe, NM, US.
- 2004. Allergy/Immunology Conference. Invited. University of Pittsburgh. Pittsburgh, PA, US.
- 2004. Cystic Fibrosis. Invited. XVIII Annual North American Cystic Fibrosis Conference. St. Louis, MO, US.
- 2004. Pediatric Pulmonary Research Seminar. Invited. Children’s Hospital of Pittsburgh. Pittsburgh, PA, US.
- 2004. Cystic Fibrosis Retreat. Invited. Children’s Hospital of Pittsburgh. Pittsburgh, PA, US.
- 2004. Wilkinsburg Meeting. Invited. Wilkinsburg, PA. Wilkinsburg, PA, US.
- 2004. T Cells and Pathogens Symposium - Experimental Biology. Invited. American Association of Immunologists Meeting. Washington, DC, US.
- 2003. Pediatric Pulmonary Research Conference. Invited. University of Pittsburgh. Pittsburgh, PA, US.
- 2003. Generation of M3-FLAG Fusion Protein as A Broad-Spectrum Chemokine Antagonist for Various Disease Models. Conference. Generation of M3-FLAG Fusion Protein as A Broad-Spectrum Chemokine Antagonist for Various Disease Models. New Orleans, LA, US.
International Presentations
- 2026. Microbes shaping host immune modulation in cancer. Invited. CNIO Distinguished Seminar Series. Madrid, ES.
- 2025. TBD. Invited. Meet the Expert Session in Pancreatic Cancer. Buenos Aires, AR.
- 2024. TBD. Invited. III HPB Hepatobiliary Pancreatic Cancer Meeting. Misiones, Iguazú, AR.
- 2024. TBD. Invited. Buenos Aires, AR.
- 2024. TBD. Invited. Program in Biomedical Sciences at the School of Medical Sciences. Rosario, AR.
- 2024. Hereditary predisposition to pancreatic cancer. Invited. ICM-International Congress Center. Munich, DE.
- 2023. Mechanisms employed by the tumor microbiome to mediate responses to immunotherapy. Invited. ESMO Immuno-Oncology Congress 2023. Geneva, CH.
- 2023. Tumor resident microbes influencing immune responses. Invited. International Cancer Immunotherapy Conference CICON23. Milan, IT.
- 2023. Microbiome and Tumor Immunology. Invited. CRO-Aviano. Aviano, IT.
- 2023. Role of Microbes in Initiation of Progression and Response to Treatment of Pancreatic Cancer. Invited. 2023 Seminars of the Institute of Experimental Genetics, School of Medical Sciences. Santa Fe, AR.
- 2023. Premalignant lesions: diagnosis, treatment and surveillance. Conference. Latin American Symposium of Oncological Gastroenterology. Viña del Mar, CL.
- 2023. Targeting the Tumor Microenvironment to Overcome Immune Resistance: Strategies and Future Directions session. Invited. ASCO GI Cancers Symposium. San Francisco, US.
- 2021. Hereditary pancreatic cancer. Concepts and recommendations. Invited. Hereditary pancreatic cancer. Concepts and recommendations. Virtual Conference, AR.
- 2021. Advances in hereditary pancreatic cancer. Genes involved and their impact on prognosis, treatment and prevention. Conference. La Academia de Ciencias Medicas de Cordoba. Virtual Conference, AR.
- 2021. Presentation in Argentina. Conference. Presentation in Argentina. Virtual Talk, AR.
- 2020. Immunology Meeting. Conference. Immunology, CL.
- 2019. Targeting Th17 Cells for the Prevention of Pancreatic Cancer. Invited. International Cancer Prevention Society (ICAPS), GB.
- 2019. The pancreatic tumor microenvironment and the influence of the gut-tumor bacterial axis. Invited. Spanish National Cancer Research (CNIO). Madrid, ES.
- 2019. Oral Discussant: New onset diabetes as a predictive factor of focal lesions in the pancreas in a high-risk screening program. Conference. ASCO. Chicago, US.
- 2018. Poster Presentation: High prevalence of hereditary cancer syndromes and outcomes in adults with early-onset pancreatic cancer. Invited. ASCO. Chicago, US.
- 2017. Special Guest Speaker. Invited. British Hospital. Buenos Aires, AR.
- 2017. IAP/LAPSG Join Meeting. Conference. UCA. Buenos Aires, AR.
- 2015. Special guest speaker. Invited. Hospital Posadas. Buenos Aires, AR.
- 2013. Role of IL-17 pathway in pancreatic cancer initiation. Conference. AACR International Meeting. San Diego, US.
- 2013. Research Seminar. Invited. Koc University School of Medicine, TR.
- 2013. Koc University School of Medicine. Invited. Research Seminar, TR.
- 2013. Cancers of the Pancreas and Small Bowel. Invited. GI ASCO Meeting. San Francisco, US.
- 2004. Lymphocytes as Effector and Regulatory Cells in TB and Pulmonary Infections Symposium. Conference. American Thoracic Society International Conference. Orlando, US.
- 2004. T Cells and Pathogens Symposium. Conference. American Association of Immunologists International Meeting. Washington, US.
- 1999. Comparative Study of Dosing Regimens in the United States and Argentina: Antiarrhythmic, Anticonvulsive and Antihypertensive Drugs. Invited. Research Day at National University of Rosario. Santa Fe, AR.
- 1999. III National Convention of Teaching Assistants in Pharmacology. Invited. National University of the Northeast, AR.
Formal Peers
- 2024. Microbial host defense and effect on cancer initiation and progression. Invited. Virtual, US.
- 2024. Mary Beth Maddox Award Lecture. Visiting. Dallas, TX, US.
- 2023. Microbial matters in pancreatic cancer. Invited. La Jolla, CA, US.
- 2023. Texas Symposium on Critical Topics in Immunology. Invited. College Station, TX, US.
- 2022. Microbial Matters in Pancreatic Cancer. Invited. Hanover, NH, US.
- 2022. Chemical biology and synthetic biology methods. Invited. Virtual Seminar, US.
- 2022. Microbial matters in Pancreatic Cancer. Invited. Virtual, US.
- 2022. Microbial Matters in Pancreatic Cancer – From Inception to Progression. Invited. Chapel Hill, NC, US.
- 2021. The Emergent Role of Microbes in Shaping Cancer Initiation and Therapy Responses. Invited. Virtual Conference, US.
- 2021. Role of Microbes in Shaping Immune Responses in Cancer and Beyond. Invited. Virtual Seminar, US.
- 2021. The Yin & Yang of Immunity in Cancer. Invited. Virtual Seminar, US.
- 2020. The role of the microbial gut-tumor axis in pancreatic tumorigenesis. Invited. Virtual Conference, US.
- 2016. Distinguished Lecturer Seminar IBT. Visiting. Houston, TX, US.
- 2011. Clinical Pharmacology Seminar. Invited. Baltimore, MD, US.
- 2004. Pediatric Pulmonary Research Seminar. Invited. Pittsburgh, PA, US.
- 2004. Cystic Fibrosis Retreat. Invited. Pittsburgh, US.
- 2003. Adult Pulmonary Research Seminar. Invited. New Orleans, LA, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Mechanisms of Intermittent Fasting in Pancreatic Cancer Prevention and Therapy |
| Funding Source: | NIH |
| Role: | PI |
| ID: | N/A |
| Date: | 2026 - 2031 |
| Title: | Role of p53 Missense Mutations on Tumorigenesis in Vivo |
| Funding Source: | NIH |
| Role: | PI |
| ID: | R01CA315085 |
| Date: | 2026 - 2030 |
| Title: | Mechanisms of improved vascular function by exercise |
| Funding Source: | ACS Research Scholar Grant |
| Role: | Co-PI |
| ID: | Pending |
| Date: | 2026 - 2031 |
| Title: | Role of gut microbes in influencing the effect of exercise on pancreatic cancer through stroma remodeling |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01, Pending |
| Date: | 2026 - 2030 |
| Title: | Pancreatic cancer immuno-prevention by ferrichrome (Subcontract) |
| Funding Source: | National Institutes of Health (NIH) subcontract via University of Texas Rio Grande Valley School of Medicine |
| Role: | Co-PI |
| ID: | FP00023305 |
| Date: | 2026 - 2031 |
| Title: | Targeting Adaptive Immune and Oncogenic Resistance to CD73 Inhibition in Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 - Subcontract |
| Date: | 2025 - 2030 |
| Title: | Mechanisms of improved vascular function by exercise |
| Funding Source: | NIH |
| Role: | Co-PI |
| ID: | R01, Pending |
| Date: | 2025 - 2030 |
| Title: | Overcoming T Cell Exclusion for Sarcoma: Molecular Mechanisms and Therapeutic Strategies |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA306978 |
| Date: | 2025 - 2030 |
| Title: | Determining the Applicability of Penile Squamous Cell Carcinoma Patient-Derived Xenograft (PDX) Models to Recapitulate the Clinical Disease |
| Funding Source: | National Institutes of Health (NIH) |
| Role: | Co-PI |
| ID: | FP00022824 |
| Date: | 2025 - 2030 |
| Title: | Role of p53 Missense Mutations on Tumorigenesis in Vivo |
| Funding Source: | National Institutes of Health (NIH) |
| Role: | Co-PI |
| ID: | CA082577 |
| Date: | 2025 - 2030 |
| Title: | Endogenous Circular RNAs limit abemaciclib anti-tumor immune responses |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA295834 |
| Date: | 2024 - 2026 |
| Title: | Tele-PancFit: Impact of video supervised exercise for patients with resectable pancreatic cancer on tumor immune cell infiltration |
| Funding Source: | National Institutes of Health (NIH) |
| Role: | PI |
| ID: | CA296244 |
| Date: | 2024 - 2027 |
| Title: | Preclinical PREVENT Cancer Program: Time-restricted feeding for Pancreatic Cancer Prevention |
| Funding Source: | National Institutes of Health (NIH) |
| Role: | PI |
| ID: | 75N91024D000041 |
| Date: | 2024 - 2029 |
| Title: | Defining pro-metastatic drivers in the pancreatic cancer tumor microenvironment |
| Funding Source: | National Institutes of Health (NIH) |
| Role: | Co-PI |
| ID: | CA269651 |
| Date: | 2024 - 2026 |
| Title: | Multi-Omics for detection of Pancreatic Cancer |
| Funding Source: | PCNA Foundation |
| Role: | Co-PI |
| Date: | 2024 - 2029 |
| Title: | Interrogating the Spatial and Functional Relevance of Microbes in Pancreatic Cancer and Metastasis |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01CA282786 |
| Date: | 2024 - 2029 |
| Title: | Improvement of PDAC Vascular Function by Exercise |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00017833_Res1 |
| Date: | 2024 - 2029 |
| Title: | Defining resistance mechanisms to CD73 inhibitors in pancreatic cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2024 - 2029 |
| Title: | The University of Texas MD Anderson Cancer Center SPORE in Melanoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00020546 |
| Date: | 2024 - 2029 |
| Title: | Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Consult |
| ID: | 2 U01 CA214263-06 |
| Date: | 2024 - 2029 |
| Title: | Next-generation vaccines for pancreatic cancer interception in high-risk individuals |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | FP00020016 |
| Date: | 2023 - 2026 |
| Title: | Preclinical PREVENT Cancer Program: Targeting the A2B Adenosine Receptor for Immunoprevention of Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 75N91019D00021/75N91020F00003 |
| Date: | 2023 - 2026 |
| Title: | Real-Time Metabolic Imaging to Interrogate Early Detection and Prevention of Pancreatic Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-PI |
| ID: | GRANT13723124 |
| Date: | 2023 - 2028 |
| Title: | A Single-Arm Phase II Study for Evaluating the Safety and Efficacy of Combination of Systematic Chemotherapy and Multiple Rounds of Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) in Patients with Pancreatic Ductal Adenocarcinoma (PDAC) |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA268046 |
| Date: | 2023 - 2024 |
| Title: | Targeting NETosis to Prevent Liver Metastasis Niche Formation |
| Funding Source: | UTMDACC GI SPORE DRP Program |
| Role: | PI |
| Date: | 2023 - 2024 |
| Title: | Developing New Genetically Tractable Chassis for Pancreatic Bacterial Tumor Therapies |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| ID: | RCTS-2023-00062100-Y1 |
| Date: | 2022 - 2025 |
| Title: | Demystifying Pancreatic Cancer Therapies (DPT) |
| Funding Source: | Break Through Cancer |
| Role: | Co-I |
| ID: | FP00016968 |
| Date: | 2022 - 2024 |
| Title: | Developing New Genetically Tractable Chassis for Pancreatic Bacterial Tumor Therapies |
| Funding Source: | Gulf Coast Consortia (GCC) |
| Role: | Co-I |
| Date: | 2022 - 2024 |
| Title: | Vaccines for Immune Interception for Pancreatic Cancer |
| Funding Source: | Moonshot Philanthropic Funds |
| Role: | Co-PI |
| Date: | 2022 - 2025 |
| Title: | Developing Imaging Biomarkers for Immunotherapy Resistance In Vivo |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Date: | 2021 - 2025 |
| Title: | Preclinical PREVENT Cancer Program: Evaluation of real-time metabolic imaging biomarkers for detection of pancreatic premalignant lesions |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 75N91019D00021/75N91020F00003 |
| Date: | 2021 - 2023 |
| Title: | PRIME-TR |
| Funding Source: | MDACC/ Moon Shots |
| Role: | PI |
| Date: | 2021 - 2026 |
| Title: | Shelby-Lavine Pancreatic Scholars Program |
| Funding Source: | Shelby-Lavine Pancreatic Scholars Program |
| Role: | PI |
| Date: | 2021 - 2026 |
| Title: | Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA248731-01A1 |
| Date: | 2021 - 2023 |
| Title: | Assessing spatial configuration and function of bacteria in pancreatic cancer and metastasis |
| Funding Source: | Robert L. Fine Cancer Research Foundation |
| Role: | PI |
| Date: | 2021 - 2021 |
| Title: | Human-to-mice fecal microbial transplants in pancreatic and colorectal cancer to sensitize tumors to immunotherapy |
| Funding Source: | MD Anderson Cancer Center SPORE in Gastrointestinal Cancer - DRP Award |
| Role: | PI |
| Date: | 2020 - 2027 |
| Title: | Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis (converted into MERIT R37- 7 years support) |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R37CA237384-01A1 |
| Date: | 2020 - 2024 |
| Title: | Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers: TO - Preclinical Testing of CD73 Inhibitors for Pancreatic Cancer Immunoprevention |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 75N91019D00021 / 75N91020F00002 |
| Date: | 2020 - 2022 |
| Title: | Genomic and therapeutic implications of selective bacterial and fungal colonization of gastrointestinal malignancies |
| Funding Source: | Sharp Innovation Award (SU2C-AACR) |
| Role: | PI |
| Date: | 2020 - 2025 |
| Title: | Modulating the Gut-Tumor Microbial Axis to Reverse Pancreatic Cancer Immunosuppression |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP200173 |
| Date: | 2020 - 2023 |
| Title: | Single-cell Evaluation to Identify Tumor-stroma Niches Driving the Transition from in Situ to Invasive Breast Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP200120 |
| Date: | 2020 - 2021 |
| Title: | Assessing the role of bacterial products in modulating cancer immune responses |
| Funding Source: | Brown Foundation |
| Role: | PI |
| Date: | 2019 - 2023 |
| Title: | Modulating pancreatic cancer immunosuppression by fecal microbial transplants |
| Funding Source: | V Foundation Translational Award |
| Role: | PI |
| Date: | 2019 - 2022 |
| Title: | Usage of Fecal Microbiota Transplantation (FMT) for Immunomodulation in Cancer |
| Funding Source: | M.D. Anderson Cancer Center/Moon Shot Fast Impact & Translation (FIT) |
| Role: | PI |
| ID: | CFS 710499-80-122165-21 |
| Date: | 2019 - 2021 |
| Title: | Pancreatic Moon Shot Philanthropic Funds, (Flagship 3), Development of Pancreatic Cancer High Risk Clinic |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Date: | 2019 - 2021 |
| Title: | Modulating tumor immune responses by bacteria present in pancreatic cancer long-term survivors |
| Funding Source: | Andrew Sabin Family Fellowship |
| Role: | PI |
| Date: | 2019 - 2021 |
| Title: | Modulating the Gut Microbiome for Prevention of Pancreatic Adenocarcinoma |
| Funding Source: | Duncan Family Institute |
| Role: | PI |
| Date: | 2019 - 2021 |
| Title: | Modulating the Gut Microbiome for Prevention of Pancreatic Adenocarcinoma |
| Funding Source: | Duncan Family Institute (DFI) |
| Role: | PI |
| ID: | 2019-00057035 |
| Date: | 2018 - 2021 |
| Title: | Manipulating the gut and tumor microbiome to induce anti-tumoral immune responses against pancreatic cancer |
| Funding Source: | Emerson Collective Award |
| Role: | PI |
| Date: | 2018 - 2021 |
| Title: | Manipulating the gut and tumor microbiome to improve pancreatic cancer outcomes |
| Funding Source: | Emerson Collective Award |
| Role: | PI |
| ID: | Fund 121454 |
| Date: | 2018 - 2019 |
| Title: | Pancreatic Moonshot Flagship Award |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Co-I |
| Date: | 2018 - 2024 |
| Title: | Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U01CA214263-01A1 |
| Date: | 2018 - 2022 |
| Title: | SUC2-Intercepting Pancreatic Cancer in High Risk Cohorts |
| Funding Source: | SU2C |
| Role: | Co-I |
| ID: | SU2C-AACR-DT25-17 |
| Date: | 2018 - 2022 |
| Title: | SUC2 - Intercepting Pancreatic Cancer in High Risk Cohorts |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | PI |
| ID: | SUC2-AACR-DT25-17 |
| Date: | 2017 - 2020 |
| Title: | Influence of the gut microbiome on pancreatic cancer through modulation of the immune system |
| Funding Source: | AGA-Bernard Lee Schwartz Research Scholar Award |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | Use of Hyperpolarization to detect Pancreatic Intraepithelial Neoplasias |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Co-PI |
| Date: | 2016 - 2018 |
| Title: | Influence of IL-17 Immune Response in Murine and Human Pancreatic Cancer Stemness and Invasiveness |
| Funding Source: | V Foundation |
| Role: | PI |
| Date: | 2016 - Present |
| Title: | Immunotherapy for Pancreatic Cancer |
| Funding Source: | Multiple Disciplinary Research Project |
| Role: | Co-I |
| Date: | 2016 - 2019 |
| Title: | Preclinical PREVENT Cancer Program: Cancer Prevention by Alpha-Enolase Vaccination |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | N01CN-2015-000018 / HHSN26100003 |
| Date: | 2016 - 2018 |
| Title: | Development of Pancreatic Cancer High Risk Clinic |
| Funding Source: | MD Anderson Cancer Center - Pancreatic Moon Shot project |
| Role: | Project PI (Flagship 3) |
| Date: | 2016 - 2018 |
| Title: | Early Detection of PanIN by Hyperpolarized metobolic MR imaging |
| Funding Source: | AACR-PanCAN Translational Award |
| Role: | Co-PI |
| Date: | 2016 - 2018 |
| Title: | Use of Hyperpolarization to Detect Pancreatic Intraepithelial Neoplasia |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Co-PI |
| Date: | 2016 - 2018 |
| Title: | K12 Paul Calabresi Career Development – K12 Scholar |
| Funding Source: | NIH/NCI |
| Role: | Scholar |
| Date: | 2016 - 2017 |
| Title: | Role of IL-17-Secreting Immune Cells in Pancreatic Cancer Stemness |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| ID: | Institutional Research Grant |
| Date: | 2016 - 2017 |
| Title: | Colorectal Cancer Pilot Moonshot Project Pembrolizumab as Colorectal Cancer Immunoprevention in Lynch Syndrome |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Project PI |
| Date: | 2015 - 2019 |
| Title: | Development of Pancreatic Cancer High Risk Clinic |
| Funding Source: | MD Anderson Cancer Center- Pancreatic Moon Shot project |
| Role: | PI |
| Date: | 2015 - 2016 |
| Title: | Modulating TH17 Cells in Pancreatic Tumorigenesis by Targeting RORgt |
| Funding Source: | National Pancreas Foundation |
| Role: | PI |
| Date: | 2014 - 2016 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | MD Anderson |
| Role: | PI |
| ID: | CCSG New Faculty Award |
| Date: | 2014 - 2016 |
| Title: | Targeting IL-17 Signaling Axis in Pancreatic Ductal Adenocarcinoma |
| Funding Source: | PanCAN– AACR Career Development Award |
| Role: | PI |
| Date: | 2014 - 2022 |
| Title: | Start-up funds |
| Funding Source: | MDACC |
| Role: | Principal Investigator-MDACC |
| Date: | 2012 - 2013 |
| Title: | Role of inflammatory cells in pancreatic tumorigenesis |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | PI |
| Date: | 2012 - 2013 |
| Title: | Role of inflammatory cells in early pancreatic tumorigenesis |
| Funding Source: | Pancreatic Cancer Action Network – AACR |
| Role: | PI |
| Date: | 2010 - 2012 |
| Title: | Discovery of novel targets for pancreatic cancer therapy |
| Funding Source: | NIH/NIGMS |
| Role: | Trainee |
| Date: | 2007 - 2008 |
| Title: | Development of novel immunological biomarkers for melanoma |
| Funding Source: | University of Pittsburgh- Shadyside Foundation Research Grant |
| Role: | PI |
| Title: | Characterize the contribution of circular RNAs to sarcoma progression and treatment response |
| Funding Source: | American Cancer Society |
| Role: | Co-PI |
| ID: | RSG-23-1037040-01-RMC |
Selected Publications
Peer-Reviewed Articles
- Bartelli, T, Baydogan, S, Sahin, I, Hoffman, KL, Petrosino, JF, Blackburn, KW, Zhao, J, Wood, A, Ayvaz, T, Surathu, A, Cagigas, MN, Barcenas, EC, Mata, T, Nguyen, VK, Zulbaran-Rojas, A, Li, L, Faraoni, EY, White, JR, Ajami, NJ, Li, L, Yadav, D, Conwell, DL, Serrano, J, Pandol, SJ, Fogel, EL, Van Den Eden, SK, Vege, SS, Topazian, M, Park, WG, Hart, PA, Forsmark, C, Bellin, MD, Maitra, A, Bhutani, M, Kim, M, Van Buren, G, Fisher, WE, McAllister, F. Whole Metagenomic Profiling Identifies a Gut Microbial Signature for Chronic Pancreatitis via Machine Learning. Pancreas 55(5):e458-e468, 2026. e-Pub 2026. PMID: 41910593.
- Haldar, SD, Saj, F, Hong, SJ, Surana, R, Xiao, L, Lee, JJ, Smaglo, BG, Zhao, D, Zhu, H, Huey, RW, Willis, JA, Morelli, MP, Overman, MJ, McAllister, F, Wolff, RA, Maitra, A, Fogelman, D, Der, CJ, Pant, S. Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. Oncologist 31(4), 2026. e-Pub 2026. PMID: 41761573.
- Sardarni, UK, Faraoni, E, Waller, AM, Strickland, LN, O’Brien, BJ, Klute, K, Cox, JL, McAllister, F, Bailey-Lundberg, JM. Dietary Fat Content Influences PanIN Progression and Pancreatic Cancer Development in Mice. Cancer Research Communications 6(5):1036-1047, 2026. e-Pub 2026. PMID: 42001482.
- Chandra, V, Li, L, McAllister, F. The Bitter Aftertaste of Artificial Sweeteners in Cancer Immunotherapy. Cancer discovery 15(11):2196-2198, 2025. e-Pub 2025. PMID: 41178349.
- Deng S, Hussain T, Bartelli TF, Sebastian MM, Zarghooni M, Velasco WV, Somerville B, Phan L, Savage MI, Song Y, Clifford JL, Kadara H, McAllister F, Brown PH, Moghaddam SJ, Aldaz CM. Repurposing of the Macrolide Antibiotic Clarithromycin for the Prevention of Lung Cancer. Mol Cancer Ther 25(2):283-294, 2025. e-Pub 2025. PMID: 41024580.
- Velasco, WV, Grimaldo, MT, Karimi, N, Clowers, MJ, Krishna, A, Wu, R, Ejaz, R, Yuan, B, Aguila, Sd, Bouchelkia, I, Barragan, JM, Larsen, KE, Rezai, Y, Khalaj, F, Mitra, K, Rodriguez, CR, Millares, R, De Anda, AB, Castro-Pando, S, Karandikar, UC, Petrosino, JF, McAllister, F, Kadara, HN, Ostrin, EJ, Fahrmann, JF, Hoffman, KL, Moghaddam, SM. Comparative effects of combustible cigarette versus electronic cigarette exposures on KRAS mutant lung cancer promotion. Neoplasia (United States) 67, 2025. e-Pub 2025. PMID: 40516145.
- Mohindroo, C, Dy, PS, Hande, SP, D’Adamo, C, Mavanur, A, Thomas, A, McAllister, F, De Jesus-Acosta, AD. New onset diabetes predicts clinical outcomes in patients with pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology 16(1):226-233, 2025. e-Pub 2025. PMID: 40115918.
- Ibrahim, RM, Solanki, S, Qiao, W, Hwang, H, Singh, BS, Cazacu, IM, Sǎftoiu, A, Katz, MH, Kim, M, McAllister, F, Bhutani, M. Fatty pancreas on EUS. Endoscopic Ultrasound 14(1):13-19, 2025. e-Pub 2025. PMID: 40151596.
- Strickland LN, Liu W, Hussein U, Mardik N, Chen X, Mills T, Vornik LA, Savage MI, Sei S, Clifford J, Eltzschig HK, Brown PH, Zhao Z, McAllister F, Bailey-Lundberg JM. Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia. Cancer Prev Res (Phila) 17(10):457-470, 2024. e-Pub 2024. PMID: 39099209.
- Castro-Pando S, Howell RM, Li L, Mascaro M, Faraoni EY, Le Roux O, Romanin D, Tahan V, Riquelme E, Zhang Y, Kolls JK, Allison JP, Lozano G, Moghaddam SJ, McAllister F. Pancreatic epithelial IL-17/IL-17RA signaling drives B7-H4 expression to promote tumorigenesis. Cancer Immunol Res 12(9):1170-1183, 2024. e-Pub 2024. PMID: 38842383.
- Li L, McAllister F, Maitra A. The liver casts a wide NET for metastatic pancreatic cancer. Nat Med 30(8):2125-2126, 2024. e-Pub 2024. PMID: 38992125.
- Mohindroo C, Baydogan S, Agarwal P, Wright RD, Prakash LR, Mork ME, Klein AP, Laheru DA, Maxwell JE, Katz MHG, Dasari A, Kim MP, He J, McAllister F, De Jesus-Acosta A. Germline Testing identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors. Cancer Prev Res (Phila) 17(7):335-342, 2024. e-Pub 2024. PMID: 38662083.
- Faraoni EY, McAllister F. Unlocking the Pancreatic Cancer Puzzle: Using Intermediate Cells to Target Treatment. Clin Cancer Res 30(11):2297-2299, 2024. e-Pub 2024. PMID: 38530840.
- Galloway-Peña J, Iliev ID, McAllister F. Fungi in cancer. Nat Rev Cancer 24(5):295-298, 2024. e-Pub 2024. PMID: 38347100.
- Rodriguez NJ, Furniss CS, Yurgelun MB, Ukaegbu C, Constantinou PE, Fortes I, Caruso A, Schwartz AN, Stopfer JE, Underhill-Blazey M, Kenner B, Nelson SH, Okumura S, Zhou AY, Coffin TB, Uno H, Horiguchi M, Ocean AJ, McAllister F, Lowy AM, Klein AP, Madlensky L, Petersen GM, Garber JE, Lippman SM, Goggins MG, Maitra A, Syngal S. A Randomized Trial of Two Remote Healthcare Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study. Gastroenterology 166(5):872-885.e2, 2024. e-Pub 2024. PMID: 38320723.
- Herman C, Barker BM, Bartelli TF, Chandra V, Krajmalnik-Brown R, Jewell M, Li L, Liao C, McAllister F, Nirmalkar K, Xavier JB, Gregory Caporaso J. Assessing Engraftment Following Fecal Microbiota Transplant. ArXiv, 2024. e-Pub 2024. PMID: 38659636.
- Chen H, Zitvogel L, Peng Z, Yin X, McAllister F. Microbiome and cancer immunotherapies. Cell Rep Med 5(4):101514, 2024. e-Pub 2024. PMID: 38631286.
- Chandra V, Li L, Le Roux O, Zhang Y, Howell RM, Rupani DN, Baydogan S, Miller HD, Riquelme E, Petrosino J, Kim MP, Bhat KPL, White JR, Kolls JK, Pylayeva-Gupta Y, McAllister F. Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation. Cancer Cell 42(1):85-100.e6, 2024. e-Pub 2024. PMID: 38157865.
- Baydogan S, Mohindroo C, Hasanov M, Montiel MF, Quesada P, Cazacu IM, Luzuriaga Chavez AA, Mork ME, Dong W, Feng L, You YN, Arun B, Vilar E, Brown P, Katz MHG, Chari ST, Maitra A, Tamm EP, Kim MP, Bhutani MS, McAllister F. New-onset diabetes is a predictive risk factor for pancreatic lesions in high-risk individuals: An observational cohort study. Endosc Ultrasound 13(2):83-88, 2024. e-Pub 2024. PMID: 38947744.
- Deng N, Reyes-Uribe L, Fahrmann JF, Thoman WS, Munsell MF, Dennison JB, Murage E, Wu R, Hawk ET, Thirumurthi S, Lynch PM, Dieli-Conwright CM, Lazar AJ, Jindal S, Chu K, Chelvanambi M, Basen-Engquist K, Li Y, Wargo JA, McAllister F, Allison JP, Sharma P, Sinha KM, Hanash S, Gilchrist SC, Vilar E. Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-associated Immunity in Lynch Syndrome. Clin Cancer Res 29(21):4361-4372, 2023. e-Pub 2023. PMID: 37724990.
- Riquelme E, Howell RM, McAllister F. Microbial Regulation of Vitamin D Linked to Colorectal Cancer: A Sex Bias. Cancer Res 83(22):3670-3672, 2023. e-Pub 2023. PMID: 37964614.
- Poplaski V, Bomidi C, Kambal A, Nguyen-Phuc H, Di Rienzi SC, Danhof HA, Zeng XL, Feagins LA, Deng N, Vilar E, McAllister F, Coarfa C, Min S, Kim HJ, Shukla R, Britton R, Estes MK, Blutt SE. Human intestinal organoids from Cronkhite-Canada syndrome patients reveal link between serotonin and proliferation. J Clin Invest 133(21), 2023. e-Pub 2023. PMID: 37909332.
- Li G, Liu L, Lu T, Sui Y, Zhang C, Wang Y, Zhang T, Xie Y, Xiao P, Zhao Z, Cheng C, Hu J, Chen H, Xue D, Chen H, Wang G, Kong R, Tan H, Bai X, Li Z, McAllister F, Li L, Sun B. Gut microbiota aggravates neutrophil extracellular traps-induced pancreatic injury in hypertriglyceridemic pancreatitis. Nat Commun 14(1):6179, 2023. e-Pub 2023. PMID: 37794047.
- Faraoni EY, Singh K, Chandra V, Le Roux O, Dai Y, Sahin I, O'Brien BJ, Strickland LN, Li L, Vucic E, Warner AN, Pruski M, Clark T, Van Buren G, Thosani NC, Bynon JS, Wray CJ, Bar-Sagi D, Poulsen KL, Vornik LA, Savage MI, Sei S, Mohammed A, Zhao Z, Brown PH, Mills T, Eltzschig HK, McAllister F, Bailey-Lundberg JM. CD73-dependent adenosine signaling through Adora2b drives immunosuppression in ductal pancreatic cancer. Cancer Res 83(7):1111-1127, 2023. e-Pub 2023. PMID: 36720042.
- Díaz-Couselo FA, Flagel S, Nicolini C, Halac S, Manzano N, Aguirre M, Rébora J, Valle S, Noro L, Mohindroo C, McAllister F, Zylberman M. Impact of high neutrophil-to-lymphocyte ratio on survival in hospitalized cancer patients with COVID-19. Cancer Med 12(6):7164-7169, 2023. e-Pub 2023. PMID: 36372937.
- Rupani DN, Thege FI, Chandra V, Rajaei H, Cowan RW, Wörmann SM, Le Roux O, Malaney P, Manning SL, Hashem J, Bailey-Lundberg J, Rhim AD, McAllister F. Adar1 deletion causes degeneration of the exocrine pancreas via Mavs-dependent interferon signaling. Development 150(2):dev201097, 2023. e-Pub 2023. PMID: 36458554.
- Baydogan S, Wright R, Kottoor RT, Kim M, Bhutani MS, McAllister F. Transient CA19-9 Elevation Post-Covid-19 Vaccine and Infection: A Case Series. Gastro Hep Advances, 2023. e-Pub 2023.
- Wright RD, Bartelli TF, Baydogan S, White JR, Kim MP, Bhutani MS, McAllister F. Bacterial and fungal characterization of pancreatic adenocarcinoma from Endoscopic Ultrasound-guided biopsies. Front Immunol 14:1268376, 2023. e-Pub 2023. PMID: 37901238.
- Kang Y, Deng J, Ling J, Li X, Chiang YJ, Koay EJ, Wang H, Burks JK, Chiao PJ, Hurd MW, Bhutani MS, Lee JH, Weston BR, Maitra A, Ikoma N, Tzeng CD, Lee JE, DePinho RA, Wolff RA, Pant S, McAllister F, Katz MH, Fleming JB, Kim MP. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. J Clin Invest 132(24):e151604, 2022. e-Pub 2022. PMID: 36282600.
- Kurz E, Hirsch CA, Dalton T, Shadaloey SA, Khodadadi-Jamayran A, Miller G, Pareek S, Rajaei H, Mohindroo C, Baydogan S, Ngo-Huang A, Parker N, Katz MHG, Petzel M, Vucic E, McAllister F, Schadler K, Winograd R, Bar-Sagi D. Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer. Cancer Cell 40(7):720-737.e5, 2022. e-Pub 2022. PMID: 35660135.
- Kasliwal S, Baydogan S, Harrison D, Mork M, Maitra A, McAllister F. Implementation of a Video-based Remote Germline Testing for Individuals With Pancreatic Ductal Adenocarcinoma. Gastroenterology 163(1):316-318.e1, 2022. e-Pub 2022. PMID: 35339459.
- Li L, Chandra V, McAllister F, Zhang Y. Mouse Models to Study Secondary Cancer Prevention. Methods Mol Biol 2435:215-223, 2022. e-Pub 2022. PMID: 34993950.
- Chang K, McAllister F, Vilar E. Transcriptomic-Assisted Immune and Neoantigen Profiling in Premalignancy. Methods Mol Biol 2435:95-105, 2022. e-Pub 2022. PMID: 34993941.
- Quesada PR, Riquelme E, Burks J, Rakoski A, Sahin I, McAllister F. Assessment of the Murine Tumor Microenvironment by Multiplex Immunofluorescence. Methods Mol Biol 2435:107-127, 2022. e-Pub 2022. PMID: 34993942.
- Chandra V, McAllister F, Burks JK. Cytometry of Mass for Murine Immunoprofiling. Methods Mol Biol 2435:129-137, 2022. e-Pub 2022. PMID: 34993943.
- Pudakalakatti S, Raj P, Salzillo TC, Enriquez JS, Bourgeois D, Dutta P, Titus M, Shams S, Bhosale P, Kim M, McAllister F, Bhattacharya PK. Metabolic Imaging Using Hyperpolarization for Assessment of Premalignancy. Methods Mol Biol 2435:169-180, 2022. e-Pub 2022. PMID: 34993946.
- Furniss CS, Yurgelun MB, Ukaegbu C, Constantinou PE, Lafferty CC, Talcove-Berko ER, Schwartz AN, Stopfer JE, Underhill-Blazey M, Kenner B, Nelson SH, Okumura S, Law S, Zhou AY, Coffin TB, Rodriguez NJ, Uno H, Ocean AJ, McAllister F, Lowy AM, Lippman SM, Klein AP, Madlensky L, Petersen GM, Garber JE, Goggins MG, Maitra A, Syngal S. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prev Res (Phila) 14(11):1021-1032, 2021. e-Pub 2021. PMID: 34625409.
- Riquelme E, McAllister F. Bacteria and fungi: The counteracting modulators of immune responses to radiation therapy in cancer. Cancer Cell 39(9):1173-1175, 2021. e-Pub 2021. PMID: 34478640.
- Kim MP, Li X, Deng J, Zhang Y, Dai B, Allton KL, Hughes TG, Siangco C, Augustine JJ, Kang Y, McDaniel JM, Xiong S, Koay EJ, McAllister F, Bristow CA, Heffernan TP, Maitra A, Liu B, Barton MC, Wasylishen AR, Fleming JB, Lozano G. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discov 11(8):2094-2111, 2021. e-Pub 2021. PMID: 33839689.
- Sinha VC, Rinkenbaugh AL, Xu M, Zhou X, Zhang X, Jeter-Jones S, Shao J, Qi Y, Zebala JA, Maeda DY, McAllister F, Piwnica-Worms H. Single-cell evaluation reveals shifts in the tumor-immune niches that shape and maintain aggressive lesions in the breast. Nat Commun 12(1):5024, 2021. e-Pub 2021. PMID: 34408137.
- Singh K, Pruski M, Bland R, Younes M, Guha S, Thosani N, Maitra A, Cash BD, McAllister F, Logsdon CD, Chang JT, Bailey-Lundberg JM. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. Lab Invest 101(2):177-192, 2021. e-Pub 2021. PMID: 33009500.
- Treekitkarnmongkol W, Hassane M, Sinjab A, Chang K, Hara K, Rahal Z, Zhang J, Lu W, Sivakumar S, McDowell TL, Kantrowitz J, Zhou J, Lang W, Xu L, Ochieng JK, Nunomura-Nakamura S, Deng S, Behrens C, Raso MG, Fukuoka J, Reuben A, Ostrin EJ, Parra E, Solis LM, Spira AE, McAllister F, Cascone T, Wistuba II, Moghaddam SJ, Scheet PA, Fujimoto J, Kadara H. Augmented Lipocalin-2 is Associated with COPD and Counteracts Lung Adenocarcinoma Development. Am J Respir Crit Care Med 203(1):90-101, 2021. e-Pub 2021. PMID: 32730093.
- Zhang Y, Chandra V, Riquelme Sanchez E, Dutta P, Quesada PR, Rakoski A, Zoltan M, Arora N, Baydogan S, Horne W, Burks J, Xu H, Hussain P, Wang H, Gupta S, Maitra A, Bailey JM, Moghaddam SJ, Banerjee S, Sahin I, Bhattacharya P, McAllister F. Interleukin-17 induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J Exp Med 217(12), 2020. e-Pub 2020. PMID: 32860704.
- Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Fogelman DR, Raghav KPS, Pant S, McAllister F. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med 9(15):5406-5415, 2020. e-Pub 2020. PMID: 32519420.
- Wasylishen AR, Sun C, Moyer SM, Qi Y, Chau GP, Aryal NK, McAllister F, Kim MP, Barton MC, Estrella JS, Su X, Lozano G. Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo. Sci Adv 6(32):eaba8415, 2020. e-Pub 2020. PMID: 32821827.
- Mendez R, Kesh K, Arora N, Di Martino L, McAllister F, Merchant N, Banerjee S, Banerjee S. Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer. Carcinogenesis 41(5):561-570, 2020. e-Pub 2020. PMID: 31369062.
- Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, Daßler-Plenker J, Guerci P, Huynh C, Knight JS, Loda M, Looney MR, McAllister F, Rayes R, Renaud S, Rousseau S, Salvatore S, Schwartz RE, Spicer JD, Yost CC, Weber A, Zuo Y, Egeblad M. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med 217(6), 2020. e-Pub 2020. PMID: 32302401.
- Dutta P, Pando SC, Mascaro M, Riquelme E, Zoltan M, Zacharias NM, Gammon ST, Piwnica-Worms D, Pagel MD, Sen S, Maitra A, Shams S, McAllister F, Bhattacharya PK. Early Detection of Pancreatic Intraepithelial Neoplasias (PanINs) in Transgenic Mouse Model by Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy. Int J Mol Sci 21(10), 2020. e-Pub 2020. PMID: 32466260.
- Goldstein JB, Zhao L, Wang X, Ghelman Y, Overman MJ, Javle MM, Shroff RT, Varadhachary GR, Wolff RA, McAllister F, Futreal A, Fogelman DR. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Pancreatic Cancer Patients. Clin Cancer Res 26(6):1385-1394, 2020. e-Pub 2020. PMID: 31871297.
- De Jesus-Acosta A, Sugar EA, O'Dwyer PJ, Ramanathan RK, Von Hoff DD, Rasheed Z, Zheng L, Begum A, Anders R, Maitra A, McAllister F, Rajeshkumar NV, Yabuuchi S, de Wilde RF, Batukbhai B, Sahin I, Laheru DA. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Br J Cancer 122(4):498-505, 2020. e-Pub 2020. PMID: 31857726.
- Singh K, Pruski MA, Polireddy K, Jones NC, Chen Q, Yao J, Dar WA, McAllister F, Ju C, Eltzschig HK, Younes M, Moran C, Karmouty-Quintana H, Ying H, Bailey JM. Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer. Oncogene 39(5):1152-1164, 2020. e-Pub 2020. PMID: 31570790.
- Cazacu IM, Luzuriaga Chavez AA, Mendoza TR, Qiao W, Singh BS, Bokhari RH, Saftoiu A, Lee JH, Weston B, Stroehlein JR, Kim MP, G Katz MH, Maitra A, McAllister F, Bhutani MS. Quality of life impact of EUS in patients at risk for developing pancreatic cancer. Endosc Ultrasound 9(1):53-58, 2020. e-Pub 2020. PMID: 31552914.
- Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, Scheet P, Xu H, Hanash SM, Feng L, Burks JK, Do KA, Peterson CB, Nejman D, Tzeng CD, Kim MP, Sears CL, Ajami N, Petrosino J, Wood LD, Maitra A, Straussman R, Katz M, White JR, Jenq R, Wargo J, McAllister F. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell 178(4):795-806.e12, 2019. e-Pub 2019. PMID: 31398337.
- Vreeland TJ, McAllister F, Javadi S, Prakash LR, Fogelman DR, Ho L, Varadhachary G, Aloia TA, Vauthey JN, Lee JE, Kim MP, Katz MHG, Tzeng CD. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas 48(6):837-843, 2019. e-Pub 2019. PMID: 31210666.
- Mork M, Quesada PR, Bannon S, Montiel MF, Fleming JB, Lynch PM, Bhutani MS, Lee JH, McAllister F. Pancreatic Cancer Early Detection and Interception in an Atypical Case of Peutz-Jeghers Syndrome. Pancreas 48(4):e29-e30, 2019. e-Pub 2019. PMID: 30973470.
- Bannon SA, Montiel MF, Goldstein JB, Dong W, Mork ME, Borras E, Hasanov M, Varadhachary GR, Maitra A, Katz MH, Feng L, Futreal A, Fogelman DR, Vilar E, McAllister F. High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. Cancer Prev Res (Phila) 11(11):679-686, 2018. e-Pub 2018. PMID: 30274973.
- Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol 4(8):1085-1092, 2018. e-Pub 2018. PMID: 29710228.
- Zhang Y, Zoltan M, Riquelme E, Xu H, Sahin I, Castro-Pando S, Montiel MF, Chang K, Jiang Z, Ling J, Gupta S, Horne W, Pruski M, Wang H, Sun SC, Lozano G, Chiao P, Maitra A, Leach SD, Kolls JK, Vilar E, Wang TC, Bailey JM, McAllister F. Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. Gastroenterology 155(1):210-223.e3, 2018. e-Pub 2018. PMID: 29604293.
- Chung L, Orberg ET, Geis AL, Chan JL, Fu K, DeStefano Shields CE, Dejea CM, Fathi P, Chen J, Finard BB, Tam AJ, McAllister F, Fan H, Wu X, Ganguly S, Lebid A, Metz P, Van Meerbeke SW, Huso DL, Wick EC, Pardoll DM, Wan F, Wu S, Sears CL, Housseau F. Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. Cell Host Microbe 23(3):421, 2018. e-Pub 2018. PMID: 29544099.
- Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2018. PMID: 29097493.
- Sahin I, Zhang Y, McAllister F. Tumor Spheres Quantification with Smoothed Euclidean Distance Transform. J Mol Imaging Dyn 8(1), 2018. e-Pub 2018. PMID: 30319887.
- Bengsch F, Knoblock DM, Liu A, McAllister F, Beatty GL. CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. Cancer Immunol Immunother 66(12):1609-1617, 2017. e-Pub 2017. PMID: 28856392.
- Bailey JM, Hendley AM, Lafaro KJ, Pruski MA, Jones NC, Alsina J, Younes M, Maitra A, McAllister F, Iacobuzio-Donahue CA, Leach SD. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. Oncogene 35(32):4282-8, 2016. e-Pub 2016. PMID: 26592447.
- Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Fowler J, Mork ME, You YN, Taggart MW, McAllister F, Jones DA, Davies GE, Edelmann W, Ehli EA, Lynch PM, Hawk ET, Capella G, Scheet P, Vilar E. Genomic Landscape of Colorectal Mucosa and Adenomas. Cancer Prev Res (Phila) 9(6):417-27, 2016. e-Pub 2016.
- Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, Peterson SN, Snesrud EC, Borisy GG, Lazarev M, Stein E, Vadivelu J, Roslani AC, Malik AA, Wanyiri JW, Goh KL, Thevambiga I, Fu K, Wan F, Llosa N, Housseau F, Romans K, Wu X, McAllister FM, Wu S, Vogelstein B, Kinzler KW, Pardoll DM, Sears CL. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A 111(51):18321-6, 2014. e-Pub 2014. PMID: 25489084.
- McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial. Cancer Biol Ther 15(6):688-98, 2014. e-Pub 2014. PMID: 24618665.
- McAllister F, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, Rattigan Y, Roeser JC, Lankapalli RH, Zhang H, Jaffee EM, Drake CG, Housseau F, Maitra A, Kolls JK, Sears CL, Pardoll DM, Leach SD. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25(5):621-37, 2014. e-Pub 2014. PMID: 24823639.
- Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W, Maitra A, Leach SD. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology 146(1):245-56, 2014. e-Pub 2014. PMID: 24096005.
- Wang YJ, McAllister F, Bailey JM, Scott SG, Hendley AM, Leach SD, Ghosh B. Dicer is required for maintenance of adult pancreatic acinar cell identity and plays a role in Kras-driven pancreatic neoplasia. PLoS One 9(11):e113127, 2014. e-Pub 2014. PMID: 25405615.
- Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA, Hidalgo M. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs 30(6):2391-9, 2012. e-Pub 2012. PMID: 22547163.
- Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ. EMT and dissemination precede pancreatic tumor formation. Cell 148(1-2):349-61, 2012. e-Pub 2012. PMID: 22265420.
- Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15(9):1016-22, 2009. e-Pub 2009. PMID: 19701202.
- Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, Reinhart TA, McAllister F, Edeal J, Gaus K, Husain S, Kreindler JL, Dubin PJ, Pilewski JM, Myerburg MM, Mason CA, Iwakura Y, Kolls JK. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14(3):275-81, 2008. e-Pub 2008. PMID: 18264110.
- McKinley L, Logar AJ, McAllister F, Zheng M, Steele C, Kolls JK. Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. J Immunol 177(9):6215-26, 2006. e-Pub 2006. PMID: 17056551.
- McAllister F, Ruan S, Steele C, Zheng M, McKinley L, Ulrich L, Marrero L, Shellito JE, Kolls JK. CXCR3 and IFN protein-10 in Pneumocystis pneumonia. J Immunol 177(3):1846-54, 2006. e-Pub 2006. PMID: 16849496.
- Zheng M, Ramsay AJ, Robichaux MB, Kliment C, Crowe C, Rapaka RR, Steele C, McAllister F, Shellito JE, Marrero L, Schwarzenberger P, Zhong Q, Kolls JK. CD4+ T cell-independent DNA vaccination against opportunistic infections. J Clin Invest 115(12):3536-3544, 2005. e-Pub 2005.
- McAllister F, Steele C, Zheng M, Shellito JE, Kolls JK. In vitro effector activity of Pneumocystis murina-specific T-cytotoxic-1 CD8+ T cells: role of granulocyte-macrophage colony-stimulating factor. Infect Immun 73(11):7450-7, 2005. e-Pub 2005. PMID: 16239546.
- Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175(9):6177-89, 2005. e-Pub 2005. PMID: 16237115.
- McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, Finder JD, Pilewski JM, Carreno BM, Goldman SJ, Pirhonen J, Kolls JK. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 175(1):404-12, 2005. e-Pub 2005. PMID: 15972674.
- McAllister F, Steele C, Zheng M, Young E, Shellito JE, Marrero L, Kolls JK. T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice. J Immunol 172(2):1132-8, 2004. e-Pub 2004. PMID: 14707088.
Invited Articles
- Riquelme E, Morgan R, McAllister F. Microbial dependent vitamin D deprivation favors colorectal cancer development. In the Spotlight. In the Spotlight. Cancer Research, 2023. e-Pub 2023.
- Li L, McAllister F. A gut reaction can tune tumour fate during chemotherapy. Nature 615(7950):36-37, 2023. e-Pub 2023. PMID: 36814015.
- Davidson NE, Gilbertson RJ, Letai A, Levine RL, McAllister F, Siu LL. Challenges and opportunities for physician-scientists in advancing cancer research. Trends Cancer 8(8):615-619, 2022. e-Pub 2022. PMID: 35717535.
- Li L, McAllister F. Too much water drowned the miller: Akkermansia determines immunotherapy responses. Cell Rep Med 3(5):100642, 2022. e-Pub 2022. PMID: 35584634.
- Chandra V, McAllister F. Therapeutic potential of microbial modulation in pancreatic cancer. Gut 70(8):1419-25. e-Pub 2021. PMID: 33906958.
- McAllister F Khan MAW, Helmink B, Wargo JA. The Tumor Microbiome in Pancreatic Cancer: Bacteria and Beyond. Cancer Cell 36(6):577-579, 2019. e-Pub 2019. PMID: 31951558.
- Riquelme E, Maitra A, McAllister F. Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling. Cancer Discov 8(4):386-388, 2018. e-Pub 2018. PMID: 29610286.
- McAllister F, Montiel MF, Uberoi GS, Uberoi AS, Maitra A, Bhutani MS. Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer. Gastroenterol Hepatol (N Y) 13(5):268-275, 2017. e-Pub 2017. PMID: 28656024.
- Roeser JC, Leach SD, McAllister F. Emerging strategies for cancer immunoprevention. Oncogene 34(50):6029-39, 2015. e-Pub 2015. PMID: 26364615.
- McAllister F, Kolls JK. Th17 cytokines in non-melanoma skin cancer. Eur J Immunol 45(3):692-4, 2015. e-Pub 2015. PMID: 25655439.
- McAllister F, Leach SD. Targeting IL-17 for pancreatic cancer prevention. Oncotarget 5(20):9530-1, 2014. e-Pub 2014. PMID: 25393980.
- McAllister F, Housseau F, Sears CL. Microbiota and immune responses in colon cancer: more to learn. Cancer J 20(3):232-6, 2014. e-Pub 2014. PMID: 24855013.
- Zhang Y, McAllister F, Pasca di Magliano M. Immune cells in pancreatic cancer: Joining the dark side. Oncoimmunology 3:e29125, 2014. e-Pub 2014. PMID: 25083330.
- Zhong W, Kolls JK, Chen H, McAllister F, Oliver PD, Zhang Z. Chemokines orchestrate leukocyte trafficking in inflammatory bowel disease. Front Biosci 13:1654-64, 2008. e-Pub 2008. PMID: 17981657.
- Dubin PJ, McAllister F, Kolls JK. Is cystic fibrosis a TH17 disease?. Inflamm Res 56(6):221-7, 2007. e-Pub 2007. PMID: 17607545.
Review Articles
- Herman, C, Barker, BM, Bartelli, T, Chandra, V, Krajmalnik-Brown, R, Jewell, M, Li, L, Liao, C, McAllister, F, Nirmalkar, K, Xavier, JB, Caporaso, JG. A review of engraftment assessments following fecal microbiota transplant. Gut microbes 17(1), 2025. e-Pub 2025. PMID: 40605266.
- Li L, Chandra V, McAllister F. Tumor-resident microbes: the new kids on the microenvironment block. Trends Cancer 10(4):347-355, 2024. e-Pub 2024. PMID: 38388213.
- Mohindroo C, McAllister F, De Jesus-Acosta A. Genetics of Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am 36(5):1033-1051, 2022. e-Pub 2022. PMID: 36154786.
- Mohindroo C, De Jesus-Acosta A, Yurgelun MB, Maitra A, Mork M, McAllister F. The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice. Surg Pathol Clin 15(3):491-502, 2022. e-Pub 2022. PMID: 36049831.
- Brandi G, Turroni S, McAllister F, Frega G. The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies?. Int J Mol Sci 22(18), 2021. e-Pub 2021. PMID: 34576078.
- Enriquez JS, Chu Y, Pudakalakatti S, Hsieh KL, Salmon D, Dutta P, Millward NZ, Lurie E, Millward S, McAllister F, Maitra A, Sen S, Killary A, Zhang J, Jiang X, Bhattacharya PK, Shams S. Hyperpolarized Magnetic Resonance and Artificial Intelligence: Frontiers of Imaging in Pancreatic Cancer. JMIR Med Inform 9(6):e26601, 2021. e-Pub 2021. PMID: 34137725.
- Dutta P, Salzillo TC, Pudakalakatti S, Gammon ST, Kaipparettu BA, McAllister F, Wagner S, Frigo DE, Logothetis CJ, Zacharias NM, Bhattacharya PK. Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic Resonance Metabolic Imaging. Cells 8(4), 2019. e-Pub 2019.
- Unver N, McAllister F. IL-6 Family Cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets. Cytokine Growth Factor Rev 41:10-17, 2018. e-Pub 2018. PMID: 29699936.
Professional Educational Materials
Other Articles
- Duan, T, Rosenbaum, A, Chandra, V, Tiraboschi, L, Rescigno, M, McAllister, F, Straussman, R, Meisel, M Toward a consensus on the tumor microbiota. Cancer cell 44(4):696-702, 2026. PMID: 41825441.
- Elinav, E, Devkota, S, Meisel, M, Zhu, S, Chu, H, Chen, H, Puschhof, J, McAllister, F, Platt, RJ, Honda, K Microbes and metabolites in immunity. Immunity 57(9):1995-1999, 2024. PMID: 39260349.
- Bradley CA Tumour microbiome defines outcomes. Nat Rev Gastroenterol Hepatol. PMID: 31477872.
- Stower H Predicting pancreatic cancer survival via the tumor microbiome. Nat Med 25(9):1330, 2019. PMID: 31501604.
- Cully M Cancer: Targeting IL-17 in pancreatic cancer. Nat Rev Drug Discov 13(7):493, 2014. PMID: 24981357.
- Vonderheide RH Tumor-promoting inflammatory networks in pancreatic neoplasia: another reason to loathe Kras. Cancer Cell 25(5):553-4, 2014. PMID: 24823632.
Editorials
- Bhutani, M, Faraoni, E, Mork, ME, McAllister, F. Gastric cancer prevention and screening during pancreatic cancer screening in high-risk individuals. Gastrointestinal endoscopy 101(5):1073-1076, 2025. PMID: 39653170.
- McAllister, F. Preface. Methods in Molecular Biology 2435:v, 2022.
- McAllister F, Mantegazza A, Garzón F, Rotbaum V, Remondino G, Vazquez Larsson M, Geffner J, Rabinovich GA, Bover L. [Use of convalescent plasma for COVID-19 treatment. History and evidence]. Medicina (B Aires) 80 Suppl 3:82-86, 2020. PMID: 32658853.
Abstracts
- Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, Scheet P, Xu H, Hanash SM, Feng L, Burks JK, Do KA, Peterson CB, Nejman D, Tzeng CD, Kim MP, Sears CL, Ajami N, Petrosino J, Wood LD, Maitra A, Straussman R, Katz M, White JR, Jeng R, Wargo J, McAllister F. Pancreatic tumor microbiome and associated immune responses determine clinical outcomes. Proceedings of the American Association for Cancer Research, 2019. e-Pub 2019.
- Zhang Y, Riquelme E, Zoltan M, McAllister F. IL 17 signaling modualtes tumor microenvironment in pancreatic cancer. Proceedings of the American Association for Cancer Research (AACR), 2019. e-Pub 2019.
- Montiel MF, Quesada PR, Dunseith M, Cazacu I, Luzuriaga A, Dong W, Mork, M, Feng L, You N, Vilar E, Arun, Brown P, Mp K, Katz MHG, Maitra A, Bhutani MS, McAllister F. New onset diabetes as a predictive factor of focal lesions in the pancreas in a high-risk screening program. Clinical Oncology, 2019. e-Pub 2019.
- Hasanov M, Fogelman DR, Pant S, Katz MHG, Kim MP, Tzeng CWD, McAllister F. The effect of antibiotic use on survival of patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 37, 2019. e-Pub 2019.
- Mohindroo C, Rogers JE, Hasanov M, Mizrahi J, Overman MO, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Pant S, McAllister F. A retrospective analysis of anitbiotics usage and effect on overall survival and progressive free survival in patients with metastatic pancreatic cancer. J Clin Oncol, 2019. e-Pub 2019.
- Dutta P, Riquelme E, Zhang Y, Salzillo T, Raj P, Lee J, Millward N, Maitra A, McAllister F, Bhattacharya, PK. Hyperpolarized magnetic reasonance metabolic imaging in pancreatic cancer research: Early detection, assessing aggressiveness and real-time monitoring treatment response. Proceedings: AACR Annual Meeting, 2018. e-Pub 2018.
- Montiel MF, Quesada PR, Dunseith M, Vilar E, Bhutani MS, Kim MP, Katz MHG, Mork ME, Arun B, Bannon SA, McAllister F. Early outcomes of a high-risk cohort in pancreatic cancer surveillance. J Clin Oncol, 36, n 15 suppl, 2018. e-Pub 2018.
- Dutta P, Riquelme E, Zhang Y, Salzillo T, Raj P, Lee J, Millward N, Maitra A, McAllister F, Bhattacharya R. Early detection of pancreatic intraepithelial neoplasms (PanINs) in transgenic mouse model by hyperpolarized C metabolic magnetic resonance imaging. AACR Annual Meeting, 2017. e-Pub 2017.
- Zhang Y, Sahin I, Gupta S, Maitra A, Bailey J, McAllister F. IL-17-secreting cells promote pancreatic stemness. Proceedings of the American Association for Cancer Research (AACR), 2016. e-Pub 2016.
- Zhang Y, Sahin I, Bailey J, McAllister F. Role of TH17 cells in promoting stemness. PanCAN Meeting, 2015. e-Pub 2015.
- McAllister F, Montiel F, Uberoi GS, Uberoi AS, Maitra A, Bhutani M. Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer. Gastoenterol Hepatol(5):268-275, 2013. e-Pub 2013.
- Bailey JM, Alsina J, Rasheed Z, Fu YY, McAllister F, Zhang H, Pasricha P, Matsui W, Maitra A, Leach SD. Pancreatic cancer tumor initiating cells are marked by the presence of cell surface acetylated alpha tubulin. Pancreatic Cancer AACR Meeting, Lake Tahoe, NV, 2012. e-Pub 2012.
- McAllister F, Bailey JM, Roeser JC, Wick E, Sears C, Kolls JK, Drake C, Pardoll DM, Leach SD. TH17 cells in Health and Disease. Keystone Symposia(AQ2):231, 2012. e-Pub 2012.
- McAllister F, Kelly L, Panelli M, Sanders C, ButterfieldL, Kirkwood J. Th17 cells are recruited to metastatic lymph nodes in patients with Stage IIIB melanoma after High-Dose IFNa2b. Proceedings of the American Association for Cancer Research (AACR), 2009. e-Pub 2009.
- McAllister F, Steele C, Zheng M, Shellito JE, Kolls JK. In vitro effector activity of Pneumocystis murina-specific T-cytotoxic-1 CD8+ T cells: role of granulocyte-macrophage colony-stimulating factor. Infect Immun 73(11):7450-7, 2005. e-Pub 2005. PMID: 16239546.
- McAllister F, Henry A, Kreindler JL, Dubin P, Ulrich L, Steele C, Finder J, Pilewski J, Carreno B, Goldman SJ, Pirhonen J, Kolls JK. Augmented IL-17 in sputum from patients with Cystic Fibrosis. Keystone Publishing, Cytokines, Disease, and Therapeutics Intervention Cytokine, 2005. e-Pub 2005.
- McAllister F, Kolls JK. IL-17A and IL17F signaling in human bronchial epithelial cells. Quantification of the upstream molecule, IL-23, in sputum from cystic fibrosis patients. Pediatric Pulmonology, 2005. e-Pub 2005.
- McAllister F, Shellito J, Steele C, Kolls JK. IP-10 Effector Activity Against Pneumocystis Carinii. Proceedings of the American Thoracic Society. Proceedings of the American Thoracic Society 2(A):A869, 2005. e-Pub 2005.
- McAllister F, Steele C, Henry A, Ulrich L, Pilewski J, Carreno B, Goldman S, Kolls JK. IL-17A and IL-17F Signaling and Pro-Inflammatory Responses in Human Bronchial Epithelial Cells. Proceedings of the American Thoracic Society 2(A):A109, 2005. e-Pub 2005.
- McAllister F, Steele C, Henry A, Ulrich L, Pilewski J, Carreno B, Goldman S, Kolls JK. Increased Expression of IL-23 and IL-17A/ IL-17F in Sputum from Patients with Cystic Fibrosis. Proceedings of the American Thoracic Society 2(A):A102, 2005. e-Pub 2005.
- McAllister F, Shellito J, Steele C, Kolls JK. In Vitro Generation of Polarized Pneumocystis Carinii-Specific CD8+ T Cells Effector Populations. Proceedings of the American Thoracic Society 2(A):A683, 2005. e-Pub 2005.
- Steele C, Finder J, McAllister F, Kolls JK. Analysis of Inflammatory biomarkers in bronchoalveolar lavage fluid from cystic fibrosis patients using Luminex technology. Pediatric Pulmonology, 2004. e-Pub 2004.
- McAllister F, Henry A, Pilewski J, Kolls JK. IL-17 pro-inflammatory responses in Human Bronchial Epithelial cells. Pediatric Pulmonology, 2004. e-Pub 2004.
- McAllister F, Steele C, Zheng M, Young E, Shellito J, Marrero L, Kolls JK. CD8+T cells against Pneumocystis. Proceedings of the American Thoracic Society, 2004. e-Pub 2004.
- McAllister F, Steele C, Zheng M, Shellito J, Marrero L, Kolls JK. Role of CD8+T cells in host defense against Pneumocystis in mice. FASEB, 2004. e-Pub 2004.
Book Chapters
- Cazacu, IM, Singh, BS, McAllister, F, Sǎftoiu, A, Bhutani, M. Pancreatic cancer screening, 39-47, 2022.
- Chandra, V, McAllister, F. Microbiome in pancreatic cancer, 283-289, 2022.
- Hasanov, M, Montiel, MF, Bhutani, M, McAllister, F. Mechanisms and evidence on pancreatic cancer prevention, 299-316, 2022.
- Li, L, Chandra, V, McAllister, F, Zhang, Y. Mouse Models to Study Secondary Cancer Prevention, 215-223, 2022.
- Chandra, V, McAllister, F, Burks, JK. Cytometry of Mass for Murine Immunoprofiling, 129-137, 2022.
- Quesada, PR, Riquelme Sanchez, EM, Burks, JK, Rakoski, A, Sahin, I, McAllister, F. Assessment of the Murine Tumor Microenvironment by Multiplex Immunofluorescence, 107-127, 2022.
- Chang, K, McAllister, F, Vilar Sanchez, E. Transcriptomic-Assisted Immune and Neoantigen Profiling in Premalignancy, 95-105, 2022.
- Pudakalakatti, S, Raj, P, Salzillo, TC, Enriquez, JS, Bourgeois, D, Dutta, P, Titus, M, Shams, S, Bhosale, PR, Kim, M, McAllister, F, Bhattacharya, PK. Metabolic Imaging Using Hyperpolarization for Assessment of Premalignancy, 169-180, 2022.
- Hasanov M, Montiel MF, Bhutani MS, McAllister F. Mechanisms and Evidence on Pancreatic Cancer Prevention. In: Pancreatic Cancer: A Multidisciplinary Approach. Springer, 2022.
- Chandra V, McAllister F. In: Microbiome in Pancreatic Cancer. Pancreatic Cancer: A Multidisciplinary Approach, 283+289, 2022.
Books (edited and written)
- McAllister F. Cancer Immunoprevention: Methods and Protocols. Ed(s) First Edition. Humana, 2022.
Patents
- Kolls JK, McAllister FM, Carreno BM, Goldman SJ. Characterization of IL-17F and IL-17R Interactions. Patent Number: 7704503.
Patient Reviews
CV information above last modified September 18, 2026